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Diverse structural solutions to catalysis in a family of antibodies
B Gigant1, T Tsumuraya2, I Fujii2* and M Knossow1*
Background: Small organic molecules coupled to a carrier protein elicit an
antibody response on immunisation. The diversity of this response has been
found to be very narrow in several cases. Some antibodies also catalyse
chemical reactions. Such catalytic antibodies are usually identified among those
that bind tightly to an analogue of the transition state (TSA) of the relevant
reaction; therefore, catalytic antibodies are also thought to have restricted
diversity. To further characterise this diversity, we investigated the structure and
biochemistry of the catalytic antibody 7C8, one of the most efficient of those
which enhance the hydrolysis of chloramphenicol esters, and compared it to the
other catalytic antibodies elicited in the same immunisation.
Results: The structure of a complex of the 7C8 antibody Fab fragment with the
hapten TSA used to elicit it was determined at 2.2 Å resolution. Structural
comparison with another catalytic antibody (6D9) raised against the same
hapten revealed that the two antibodies use different binding modes.
Furthermore, whereas 6D9 catalyses hydrolysis solely by transition-state
stabilisation, data on 7C8 show that the two antibodies use mechanisms where
the catalytic residue, substrate specificity and rate-limiting step differ.
Conclusions: Our results demonstrate that substantial diversity may be present
among antibodies catalysing the same reaction. Therefore, some of these
antibodies represent different starting points for mutagenesis aimed at boosting
their activity. This increases the chance of obtaining more proficient catalysts
and provides opportunities for tailoring catalysts with different specificities.
Introduction
The concept that a higher affinity of an enzyme for a
transition state compared with substrate increases the rate
of the corresponding chemical reaction dates back to
Pauling [1]. It was then predicted by Jencks that anti-
bodies raised against a chemically stable transition-state
analogue (TSA) could catalyse this reaction [2]. Since the
first experimental reports of catalytic antibodies [3,4],
more than 80 different antibody-catalysed reactions have
been catalogued, corresponding to all but one of the
major enzyme classes [5]. Although some antibodies have
been reported to have an efficiency similar to or better
than that of the corresponding enzyme [6], in a number of
cases it has been difficult to obtain such high efficiencies
using the approach proposed by Jencks, and improve-
ment of catalytic antibody efficiency is one of the major
challenges in the field [7]. Ways have been sought to
boost this efficiency either by site-specific mutagenesis
[8–10] or by a more systematic approach based on
libraries of mutated antibodies [11]. As immunisation
with a TSA hapten usually gives rise to several catalysts,
the question arises of which antibody to choose as a start-
ing point for engineering. When the binding modes of
these catalysts are all very similar, modifications of any of
them would be sufficient to explore all the possibilities
for improvement; if the binding modes are dissimilar,
mutagenesis of different antibodies might give rise to dif-
ferent optimised efficiencies. 
The genetic diversity of the antibody response to a
number of model haptens has been studied by sequence
analysis and, in general, the response to simple epitopes is
found to be very restricted and is characterised as idiotypic
[12]. In a few cases these studies have been completed by
determination of the structures of one or two of the
elicited antibodies [13–15]. In one case, when sequences
of antibodies specific for 2-phenyloxazolone were analysed
in the context of the structure of one of them, the conclu-
sion was reached that the immune system sees the hapten
by a very limited number of principal mechanisms [15]; in
another case, however, two binding modes were identified
[13,14]. As catalytic antibodies are usually identified
among those that bind tightly to the TSA hapten and as
they undergo further screening for catalytic activity, their
diversity of binding mode is expected to be even more
restricted than that of hapten-binding antibodies. Anti-
bodies resulting from a single immunisation have been
defined as belonging to ‘a family of antibodies’. A high
degree of sequence identity between catalytic antibodies
of the same family has been reported in several cases
[16–18], and when structures were determined, they were
found to have many similar features [19,20]. In contrast to
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these findings, we report here the structure of a catalytic
antibody that binds its corresponding TSA hapten in a
mode that is totally different from that used by other cat-
alytic antibodies recovered from the same immunisation.
Antibody 7C8 was raised against the chloramphenicol
phosphonate derivative (1; Figure 1) and catalyses the
hydrolysis of the corresponding ester (2) with significant
rate enhancement to generate chloramphenicol (3) and
the acid product [21]. Five other catalysts were recovered
from the same immunisation. These five antibodies share
a high degree of sequence similarity [22]. Antibody 6D9,
the best of these five catalysts, was characterised in detail
[21] and its structure determined by X-ray crystallogra-
phy [23]. The degree of similarity of the 7C8 variable
domain amino acid sequences to those of the other five
antibodies is close to 50%; despite these differences, 7C8
is as efficient as 6D9 (kcat values are 0.115 min–1 and
0.145 min–1, respectively). We have determined the
structure of the 7C8 Fab fragment (the antigen-binding
fragment) complexed with the phosphonate transition
state analogue 1 and show that antibodies 7C8 and 6D9
bind their common TSA hapten through different modes;
this accounts for their different specificities. We also
show that the catalytic residues involved and the rate-
limiting steps, and therefore the mechanisms, of these
two antibodies differ.
Results and discussion
Overview of the structure
The crystal structure of the 7C8 Fab was determined at
2.2 Å resolution. There are two Fab molecules in the
asymmetric unit of the 7C8 crystal; the elbow angles of
the two Fabs are in the observed range for antibodies but
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Figure 1
Chemical formulae of the compounds used in
this study. Antibody 7C8 was raised against
the chloramphenicol phosphonate 1 and
catalyses the hydrolysis of the
chloramphenicol ester 2 to generate the acid
product and chloramphenicol 3. TSA 4 was
used to elicit the p-nitrobenzyl ester
hydrolysing antibody D2.3 [49].
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differ by 8°. Several other antibodies for which Fab struc-
tures have been determined by X-ray crystallography have
been observed to adopt different elbow angles in each of
the copies of their Fabs in the asymmetric unit [24]; the
accumulated evidence therefore supports the idea that the
elbow angle is influenced by the environment and in par-
ticular by crystal packing. 
The overall shape of the antibody combining site (the
antigen-binding site), where the hapten TSA 1 is located, is
a shallow groove rather than the deep pocket commonly
found in antibody structures whose antigen is a small
hapten [25]. This results in only 60% of the surface area of
the ligand being buried in the combining site and may
account for the relatively high value of the dissociation con-
stant Kd (0.3 µM) of the antibody for hapten 1 [21]. The tri-
fluoroacetamide moiety of the hapten (Figure 2) and the
attachment site for the carrier protein used for immunisa-
tion represent 75% of the surface remaining accessible after
binding of 1 to the Fab. Probably because of its relatively
limited contacts with the Fab, the trifluoroacetamide
moiety of the hapten is in poorly defined electron density,
and the temperature factor for this part of the ligand is sig-
nificantly higher than the average B factor of the ligand
(36 Å2 versus 17 Å2, averaged over the two molecules of the
asymmetric unit). The contacts to this part of the hapten
are made by two residues at the tip of the hypervariable
loop H3; in H3 only two other residues, TyrH95 and
PheH100a (where H denotes heavy chain; residue number-
ing is according to [26]), contact the hapten (Figure 2).
The structures of eight antiphosphonate hydrolytic anti-
bodies belonging to four different families have been
determined previous to those of the 7C8/6D9 family. It was
noticed that the related hapten ligands of these antibodies,
which all comprise an aryl phosphonate moiety, are bound
in such a way that their aromatic part is deeply buried in a
semiconserved hydrophobic pocket of the antibody com-
bining site at the interface of the heavy- and light-chain
variable domains [27]. Here, as in 6D9 [23], the hapten is
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Figure 2
The antibody 7C8–TSA 1 interface.
(a) Stereoview of a 2Fo–Fc electron-density
map contoured at the 1σ level in the
combining site of one of the Fab molecules in
the asymmetric unit. The contribution of the
atoms of the hapten was omitted in the
calculation of the map. Atoms are colour
coded: carbon, yellow; nitrogen, blue; oxygen,
red; chlorine, green; fluorine, pink;
phosphorus, magenta. (b) Schematic
stereoview of the 7C8 active site (in green) in
complex with TSA 1 (in blue). Atoms are
colour coded: chlorine, grey; fluorine, purple;
and phosphorus, yellow. A water molecule is
shown as a red sphere and labelled (Wat).
Hydrogen bonds are shown as broken lines.
Only residues discussed in the text are
represented. (Part (a) was rendered in the
program O [43]; part (b) was rendered with
the program MOLSCRIPT [50].) 
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bound on the surface of the combining site and its nitro
group, although completely buried in the antibody, is dis-
placed by 6 Å towards the outside of the site as compared
with the equivalent group in the complex of antibody D2.3
with its hapten (Figure 3). Accordingly, in D2.3, which is
representative of the hapten-binding mode of the four fam-
ilies of catalytic antibodies studied previously [27], the
hapten buries 90% of its surface in contrast to 60% in 7C8.
To gain further insight into the reason for the different
binding modes observed in 7C8 and other esterase-like
antibodies, antibody D2.3 was used as their prototype. The
p-nitrobenzyl and phosphonate groups of 1 and of the D2.3
hapten TSA 4 in its complex with D2.3 were superim-
posed; when this is done, one finds that the substituents to
the benzylic carbon of 1 are too bulky to be accommodated
in the D2.3 combining site. Such a superposition would, in
particular, cause steric hindrance between the light-chain
framework and the dichloroacetamide group of 1 (data not
shown); therefore the structure adopted by 7C8 differs
from that of D2.3. The deeply buried pocket of the com-
bining site occupied by the NO2 group in all the com-
plexes of esterase-like catalytic antibodies studied
previously is closed by two residues in 7C8. These residues
are HisL89, provided by complementarity-determining
region (CDR) L3, and PheH100a, which belongs to the
bulge found in CDR H3 of 7C8 as well as in all H3 loops
with an arginine or a lysine at position H94 [28]. By com-
parison, in D2.3, residue L89 (where L denotes light chain)
is a valine, much smaller than histidine, and the bulge of
the H3 loop is oriented such that the sidechain of residue
100f, which corresponds to H100a in 7C8 when 7C8 and
D2.3 are superimposed, faces towards the outside of the
antibody (Figure 3), whereas in 7C8 the H100a sidechain
points towards the combining site (Figure 2).
The hapten–antibody interface: structural basis for
substrate specificity
The substrate specificity of 7C8 has been established [21];
it is accounted for by the structure of the 7C8–TSA 1
complex. This is best analysed by considering in turn the
four substituents that surround the phosphonate of 1 and
mimicking the reaction centre of the ester to be hydrol-
ysed (Figure 2). Substitutions at positions of the substrate
equivalent to atoms in the hapten that have little contact
with the Fab allow catalysis to be maintained. First, the
hydroxyl group involved in the attachment of the hapten
to the carrier protein does not interact with the antibody
combining site. A modification of this hydroxyl has little
effect on the rate enhancement and on the Michaelis con-
stant KM. Second, in the same way, the conversion of the
trifluoroacetyl group to an acetyl group is also without con-
sequence, in agreement with the limited contacts of this
part of the hapten with the antibody. On the contrary, the
p-nitrobenzyl group of 1 points towards the inside of the
combining site and makes tight interactions with the Fab:
the aromatic ring is stacked between the sidechains of
TyrH95 and TrpH50 and the nitro group establishes a
hydrogen bond with the AsnH35 sidechain. Consistently,
the introduction of a bulky p-dichloroacetamide function
instead of the p-nitro group results in an ester which is not
a substrate of antibody 7C8.
Finally, the dichloroacetamide moiety of 1 is located on
the surface of the antibody and its interactions with 7C8
influence the catalytic properties in a more subtle way
than those of the trifluoroacetyl and p-nitrobenzyl groups.
The dichloroacetamide group establishes van der Waals
contacts and two hydrogen bonds with the L3 hypervari-
able loop of the antibody; additional interactions are
mediated by a water molecule (Figure 2). The substitu-
tion of the dichloroacetamide by an acetylamide group
results in a tenfold reduction of hydrolytic activity but in
an identical KM value. The substitution involves a group
that is separated from the reaction centre by six covalent
bonds. Interactions of a biocatalyst with substrate atoms
distant from the reaction centre that contribute to rate
acceleration and do not affect substrate binding have
been observed in enzymes and in serine proteases in par-
ticular [29] and have also been documented in the case of
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Figure 3
Comparison of the location of (a) the hapten
1 in the active site of 7C8 and (b) the hapten
4 in the combining site of antibody D2.3 [19].
The ligands are drawn in blue, heavy chains
are in yellow and the light chains in green. In
7C8, the sidechains of residues L89 and
H100a that prevent deeper burying of the
nitro group of the hapten are represented;
residues labelled in D2.3 are the equivalent
residues identified from the superposition of
7C8 with D2.3. (The figure was rendered with
the program MOLSCRIPT [50].)
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a catalytic antibody [30]. 7C8 provides another example
of an interaction at a distance from the reaction centre
that affects catalysis, a feature reminiscent of enzymes.
Although they were elicited in the same immunisation,
antibodies 6D9 and 7C8 accommodate their common
hapten 1 in different ways (Figure 4). It is noteworthy that
the TSA 1 has two distinct conformations in these anti-
bodies. Whereas it is extended in the 7C8–TSA 1 struc-
ture, it is folded in the 6D9–TSA 1 complex, with its two
aromatic rings stacked. As a consequence of the different
binding modes of 7C8 and 6D9 their substrate specifici-
ties differ. Whereas 7C8 accepts significant changes to the
acetyl substituent of its substrate, this is not the case for
6D9. This is accounted for by the structures: in the
7C8–TSA 1 structure the trifluoroacetyl group is exposed
to the solvent whereas it is deeply buried in the
6D9–TSA 1 complex.
The most efficient antibodies of the 7C8/6D9 family use
different catalytic mechanisms
Ester hydrolysis at alkaline pH involves the formation of
an oxyanion intermediate which subsequently decom-
poses to the acid and alcohol products. Phosphonate TSAs
have been designed to mimic this intermediate; the anti-
bodies they elicit stabilise the phosphonate TSA and pre-
sumably the oxyanionic transition state better than the
ester bond of the substrate and the target reaction is there-
fore catalysed. This principle has been ratified by all the
structures of esterase-like antibodies determined so far
[27,31]. Antibodies 6D9 and 7C8 bind the phosphonate of
TSA 1 by establishing one hydrogen bond with it, whereas
the second phosphonyl oxygen remains accessible to
solvent after complex formation both in 6D9 and 7C8. As
the structures differ, the residues providing the hydrogen
bond donor group are different. In 6D9, a histidine of
CDR L1 provides the hydrogen-bond to the phosphonate
of 1 and has been shown by site-specific mutagenesis [32]
to be the main residue responsible for catalysis. In 7C8,
TyrH95 is the hydrogen-bond donor (Figure 2). The pH
profile of the 7C8-catalysed reaction rate (Figure 5) shows
an acid limb below pH 9 and is consistent with the
involvement of TyrH95 in the mechanism. Apart from the
catalytic residue, another feature differentiates catalysis
by 7C8 and 6D9: addition of hydroxylamine, a better
Research Article  Diversity in a catalytic antibody family Gigant et al. 1389
Figure 4
Comparison of the conformation of TSA 1 in
the active site of (a) 7C8 and (b) 6D9 (same
colour code as in Figure 2b). The combining
sites are shown in the same orientation. In
each case, the hydrogen bond established
with the phosphonyl oxygen by the residue
identified as catalytic is represented by a
broken line. (The figure was rendered with the
program MOLSCRIPT [50].)
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Figure 5
The pH dependence of the rate of catalysis (V) of substrate 2
hydrolysis by the antibodies 7C8 (large squares) and 6D9 (small
diamonds) (for details, see the Materials and methods section). The
logarithm of the 6D9 rate is a linear function of pH in the range
explored, whereas that of the 7C8 rate shows an acid limb at pH 9.
This observation is consistent with the participation of a tyrosine
residue in the catalytic mechanism of 7C8.
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nucleophile than the hydroxide ion, enhances the rate of
hydrolysis of ester 2 by 6D9 but leaves that of 7C8 unaf-
fected (Figure 6). This shows that, in contrast to 6D9,
nucleophilic attack by an hydroxide ion is not the rate-lim-
iting step in catalysis by 7C8.
Whereas the kinetic data in conjunction with the
7C8–TSA 1 structure identify TyrH95 as one of the
residues involved in catalysis, the exact role of this
residue is more ambiguous. The pH profile is consistent
both with TyrH95 being part of the oxyanion hole and
with it having the role of a nucleophile. In the first case,
TyrH95 would participate in catalysis by stabilising the
transient oxyanion during ester hydrolysis, as planned by
the TSA hapten. In this case, the nucleophile is an
hydroxide ion; the rate is a function both of hydroxide ion
concentration and of the proportion of TyrH95 that is pro-
tonated. Above its pKa, TyrH95 becomes deprotonated,
and this accounts for the plateau of the pH profile at high
pH. If oxyanion stabilisation was the actual mechanism
used by 7C8, the simplest interpretation of the pH profile
suggests that OH– attack would be the rate-determining
step, which is inconsistent with the insensitivity of the
rate to the addition of hydroxylamine. Therefore one
needs to consider an alternative mechanism consistent
with the pH rate profile, namely that in which TyrH95 is
a nucleophile. In this case, the pH profile can be inter-
preted as follows: the tyrosine becomes a better nucle-
ophile as it gets deprotonated and the rate would reach a
plateau when deprotonation is complete. With this mech-
anism, the insensitivity of the rate to addition of hydroxy-
lamine means that the rate-determining step is likely to
be the nucleophilic attack by deprotonated tyrosine. For
nucleophilic attack by TyrH95 to be a possible mecha-
nism, the observed catalytic rate must be consistent with
known values of the rates of all steps of this mechanism,
and in particular with that of TyrH95 deacylation. The
rate of the 7C8-catalysed reaction is approximately
100 times faster than the rate of uncatalysed hydrolysis of
model tyrosine esters [33,34] so that, in order for nucle-
ophilic attack by TyrH95 to be the major cause of cataly-
sis by 7C8, deacylation of this residue needs to be
assisted. A movement of the LysL32 sidechain (Figure 4)
would bring it into a position to assist water activation.
Unless this movement, or another structural rearrange-
ment of the combining site, occurs during the reaction
that positions a residue correctly to assist deacylation, a
more complex mechanism would need to be advocated.
Biological implications
The diversity that allows protection against an enormous
variety of unrelated pathogens is one of the fundamental
properties of the antibody repertoire. Despite this, the
diversity of the antibodies elicited by haptens is restricted,
as is the diversity of the families of catalytic antibodies
studied to date. In contrast to these findings, we identify
here two different substrate-binding modes in a family of
antibodies that hydrolyse chloramphenicol esters.
Chloramphenicol inhibits bacterial growth by binding to
the 50S subunit of the ribosome, an effect which is pre-
vented when this antibiotic is acetylated. Chlorampheni-
col and its monoester derivatives therefore constitute a
good model system for the catalytic antibody approach to
prodrug activation. With this goal in mind, a family of
antibodies has been elicited by immunisation with a
phosphonate transition-state analogue of chlorampheni-
col monoester hydrolysis. These antibodies catalyse this
reaction with significant rate enhancement and multiple
turnovers and the most efficient of them inhibits bacter-
ial growth when the medium is supplemented with this
chloramphenicol monoester. 
Although the hapten used to elicit this family of antibod-
ies contains proximal aromatic and phosphonate groups,
as do all the haptens used so far to elicit esterase-like
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Figure 6
The effect of hydroxylamine on the catalytic
activity of (a) 7C8 and (b) 6D9. For
experimental details, see the Materials and
methods section. Small diamonds, overall
rate; large squares, background rate without
antibody; small circles, catalysed reaction
rate. The velocity of the 6D9-catalysed
reaction is enhanced by hydroxylamine,
whereas that of the 7C8-catalysed reaction is
unaffected by this compound.
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antibodies that have been studied structurally, the
binding modes used by these chloramphenicol-
hydrolysing antibodies differ from the common binding
mode identified in all other esterase-like antibodies.
Moreover, the binding modes of the two most efficient
antibodies differ from each other and, as a consequence,
their specificities, rate-limiting steps and catalytic
residues are different as well. This demonstrates that, at
least in this case, several catalytic solutions are elicited
through the immune response to a transition-state ana-
logue hapten. These antibodies represent distinct starting
points for the designed improvement of the efficiency of
these catalysts and each one provides additional opportu-
nities for reaching a higher optimised efficiency. 
Finally, because of the way they were selected, the cat-
alytic antibodies studied here represent a subset of those
that efficiently bind a transition-state analogue hapten.
Therefore, the diversity we identified applies not only to
catalytic antibodies but more generally to the binding
modes provided by the immune system in response to a
single hapten molecule. 
Materials and methods
Purification, crystallisation and data collection
The 7C8 antibody was purified from the ascitic fluid as described [35].
The Fab was generated by papain digestion of the antibody in standard
conditions (30 mM Tris pH 7.4, 138 mM NaCl, 1.25 mM EDTA, 1.5 mM
2-mercaptoethanol) using a 3% papain to antibody ratio (w/w) and a
8.5 h digestion time. The Fab was purified by DEAE anion exchange
chromatography followed by gel filtration.
For crystallisation, the Fab in 150 mM NaCl was concentrated to
5 mg/ml and complexed with TSA in a 1.1 M excess. Initial conditions
yielding small twinned crystals were identified by sparse matrix screen-
ing [36]. The precipitant identified by this procedure comprised: 30%
(w/v) polyethylene glycol (PEG) 8000, 0.2 M ammonium sulphate pH 4.
Single crystals were obtained in 22% to 26% (w/v) PEG 1000, 0.2 M
ammonium sulphate pH 4, following streak-seeding and macro-seeding.
A data set (data set 1) collected on a Rigaku R200 rotating-anode gen-
erator equipped with an Raxis II image-plate system was used for mol-
ecular replacement. Higher resolution data (up to 2.2 Å) were collected
at the W32 station of the LURE synchrotron (Orsay, France) on a Mar-
Research image-plate (data set 2). Both data sets were indexed and
integrated with DENZO and scaled and merged with SCALEPACK
[37]. Data collection statistics are summarised in Table 1.
Structure determination and refinement
The 7C8 Fab crystallises in the P21 space group; the unit-cell dimen-
sions suggest that there are two Fab molecules in the asymmetric unit.
The 7C8 Fab structure was solved by molecular replacement using
data from data set 1 between 15 Å and 4 Å, with the program AMoRe
[38]. The search models were the constant and the variable domains of
the anti-lysozyme antibody D44.1 [39] taken separately (PDB code
1MLB [40]). This antibody was chosen from those for which Fabs are
structurally known because it has the highest sequence similarity with
7C8, as detected by the program BLAST [41]. After molecular replace-
ment, the R factor was 41%. We then alternated refinement using the
conjugate gradient facility of X-PLOR [42] and reconstruction with the
program O [43]. Progress of the refinement was judged by the
decrease of the free R factor [44], calculated with 5% of the observa-
tions that were not included in the refinement. During refinement, we
applied noncrystallographic symmetry restraints separately between
the two Fvs (variable domains dimers) of the asymmetric unit on the
one hand and between the two constant domains of the asymmetric
unit on the other. This accounts for the fact that the elbow angles of the
two Fabs differ (134° and 142°, respectively). The restraints were strict
during the first rounds of refinement (at this stage the rmsd between
the equivalent domains of the two Fabs of the asymmetric unit was less
than 0.03 Å), and were subsequently relaxed as long as this improved
the free R factor [45]. The hypervariable loops were reconstructed in
2Fo–Fc and Fo–Fc omit maps. When all the residues had been incorpo-
rated, temperature factor refinement and coordinate refinement were
performed alternately. The ligand constructed manually in the density in
the antibody combining site was then incorporated into the refinement
process. Its position was initially defined by the three highest peaks in a
Fo–Fc map, which were attributed to its phosphorus and two chlorine
atoms. Water molecules were identified at positions above four stan-
dard deviations in this map, and one peak per Fab was attributed to a
sulphate ion, consistent with the shape of the electron density and with
the ions present in the crystallisation buffer. Refinement statistics are
presented in Table 2. At the end of the refinement, more than 86% of
the residues of 7C8 Fab have ψ and φ dihedral angles in the most
favourable regions of the Ramachandran plot, as evaluated with the
program PROCHECK [46]. There are three outliers: two of them are in
a loop of the constant region for which there is no density, the other
one is the residue L51 of the L2 CDR, which adopts in 7C8 the ubiqui-
tous conformation of this residue in antibodies [47].
Superposition of atomic models was done with program O [43].
Accessible surface areas were calculated using the algorithm of
Shrake and Rupley [48].
Dependence of the rate of catalysis on pH
The variation of the initial rate of hydrolysis of substrate 2 catalysed by
antibodies 7C8 and 6D9 as a function of pH was determined between
pH 6.4 and 11.1 in ATE buffer (100 mM ACES, 52 mM Tris, 52 mM
ethanolamine). Reactions were initiated by adding 10 µl of a 2 mM solu-
tion of substrate 2 in DMSO to 90 µl of 1.1 µM antibody solution in ATE
buffer at 25°C (final concentrations of substrate and antibody are
200 µM and 1.0 µM, respectively). Hydrolysis rates were measured by
high pressure liquid chromatography (HPLC) analysis of the products in
10 µL aliquots of the reaction mixture as described [21] and were cor-
rected for the uncatalysed rate of hydrolysis in the absence of antibody.
Hydroxylamine partitioning studies
The following stock solutions were prepared: 5 mM chloramphenicol
ester 2 in DMSO; 1.67 µM antibody (7C8 or 6D9) in 50 mM Tris-HCl
pH 8.0; 300 mM hydroxylamine in 50 mM Tris-HCl pH 8.0. Initial rate
measurements were carried out at 25 °C in reaction volumes made up
with 0–30 µl of hydroxylamine stock solution, 60 µl antibody stock
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Table 1
Diffraction data statistics.
Data set 1 Data set 2
Wavelength (Å) 1.54 0.97
Resolution limit (Å) 2.8 2.2
Observations 35,325 98,277
Unique reflections 18,796 40,238
Completeness (%)* 91.4 (73.3) 97.9 (95.7)
Rsym (%)*† 8.6 (27.6) 6.6 (25.3)
I/σ(I)* 9.3 (2.7) 15.2 (5.4)
Unit-cell dimensions for both data sets were a = 54.6 Å, b = 65.6 Å, c
= 117.8 Å, β = 95.6° (α = γ = 90°). *Values in parentheses are for the
highest resolution shell. †Rsym = ΣΣj|Ij–<I>|/Σ|<I>|, where Ij is the
intensity measurement for reflection j and <I> is the mean intensity for
multiply recorded reflections.
solution and completed to 90 µl with reaction buffer (50 mM Tris-HCl
pH 8.0). Reactions were initiated by adding 10 µl substrate stock solu-
tion to the mixture. Formation of chloramphenicol was measured by
HPLC as described above.
Accession numbers
The coordinates have been deposited in the Protein Data Bank with
accession code 1CT8.
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